Sanofi-Aventis To Assume Development Of Phase III Anticancer Agent S-1
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi will pay Taiho Pharmaceutical up to $360 mil. for S-1, which combines two enzyme inhibitors with the 5-FU prodrug tegafur.